Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
January 16 2024 - 8:30AM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the
appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan
will lead the global clinical development, clinical operations, and
safety programs for Mirum’s pipeline of programs addressing rare
diseases.
Dr. Quan was most recently Chief Medical Officer at Nuvig
Therapeutics. Prior to Nuvig, she served in the same role at Modis
Therapeutics, a company focused on rare genetic diseases (acquired
by Zogenix, Inc. and subsequently UCB). Before Modis, she held
clinical development leadership positions at Eiger
Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill
Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech,
and PathoGenesis. Dr. Quan received a BA in molecular biology at
the University of California, Berkeley, and an MD at Stanford
University School of Medicine. She completed a residency in
internal medicine at Massachusetts General Hospital and a
fellowship in pulmonary and critical care medicine at the
University of Washington.
In tandem with Dr. Quan’s appointment, Mirum announced the
promotion of Peter Radovich to President and Chief Operating
Officer. Mr. Radovich oversees commercial, corporate development
and supply chain functions for Mirum.
“Joanne brings nearly three decades of experience in the
development of medications for rare conditions. I’m thrilled that
she is joining at such an exciting time for Mirum, strengthening
our team and leadership in rare disease,” said Chris Peetz, Chief
Executive Officer at Mirum. “I am also excited about the promotion
of Peter Radovich, whose contributions have helped place Mirum in a
position of strength, with an expanded portfolio of three growing
commercial medicines. I am proud of the expertise we have assembled
at Mirum to bring life-changing medicines to patients around the
world.”
“Mirum has achieved wonderful success both clinically and
commercially, establishing itself as the leader in cholestatic
liver disease with a deep and focused commitment to patients,” said
Joanne Quan, MD. “I am excited to join at such an important time as
the company grows its pipeline, continues to extend its reach to
patients globally, and builds upon its success and commitment as a
rare disease company.”
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare diseases affecting
children and adults. Mirum has three approved medications:
LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid)
capsules, and Chenodal® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of
cholestatic pruritus in patients with Alagille syndrome in the U.S.
(three months and older), in Europe (two months and older), and in
Canada. Mirum has also submitted LIVMARLI for approval in the U.S.
in cholestatic pruritus in PFIC patients three months of age and
older and in Europe in PFIC for patients two months of age and
older. Cholbam is FDA-approved for the treatment of bile acid
synthesis disorders due to single enzyme defects and adjunctive
treatment of peroxisomal disorders in patients who show signs or
symptoms or liver disease. Chenodal has received medical necessity
recognition by the FDA to treat patients with cerebrotendinous
xanthomatosis (CTX).
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases. Volixibat, an IBAT
inhibitor, is being evaluated in two potentially registrational
studies including the Phase 2b VISTAS study for primary sclerosing
cholangitis and Phase 2b VANTAGE study for primary biliary
cholangitis. Lastly, Chenodal, has been evaluated in a Phase 3
clinical study, RESTORE, to treat patients with CTX.
To learn more about Mirum, visit mirumpharma.com and follow
Mirum on Facebook, LinkedIn, Instagram and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240116855446/en/
Media: Erin Murphy 510-508-6521 media@mirumpharma.com
Investors: Andrew McKibben ir@mirumpharma.com
Sam Martin Argot Partners ir@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2024 to May 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From May 2023 to May 2024